Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era
Endocrinology, Diabetes & Metabolism · 2026-09 · 9 (5)
DOI: 10.1002/edm2.70298 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 30.07.2026. Verfasst von Zakariye Isak Mohamed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia. Hauptthemen laut MEDLINE: Tirzepatide, Heart Failure, Obesity, Stroke Volume. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalizations, with obesity increasingly recognized as a central driver through expansion of epicardial adipose tissue, chronic low‐grade inflammation and obesity‐related haemodynamic overload culminating in ventricular hypertrophy.
Methods
We synthesized high‐impact evidence from pivotal randomized trials and mechanistic studies published between 2015 and 2026, focusing on cardiometabolic outcomes, adipose tissue remodelling and haemodynamic effects of both drug classes.
Results
Tirzepatide produced substantial weight loss (> 20%), significant reductions in epicardial and paracardiac adipose tissue and a 19.5‐point improvement in Kansas City Cardiomyopathy Questionnaire scores in the SUMMIT trial. SGLT2i, exemplified by empagliflozin, demonstrated foundational benefit through natriuresis, improved myocardial energetics and reduced heart failure hospitalization independent of diabetes status, with additional renal‐protective effects. Because SUMMIT and EMPEROR‐Preserved differed in design and populations, direct comparison between agents is not statistically valid; each should be assessed on its own evidence base.
Conclusion
Tirzepatide and SGLT2i act through distinct, physiologically complementary pathways converging on the cardio‐renal‐metabolic axis. While their combined use is mechanistically promising, it has not yet been tested in a dedicated randomized controlled trial, and prospective studies are needed to establish safety and long‐term efficacy in obesity‐related HFpEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Department of Cardiology, Jazeera Specialist Hospital, Mogadishu, Somalia.
- Department of Pharmacology, Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia.
ORCID-Profile: Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed
Zitieren
APA
Mohamed, Z. I., Shidane, A. A., Abdiasis, A. M., Hussein, M. H., Ibrahim, A. O., Abdi, A. A., Hashi, K. I., Mohamud, M. A., & Mohamed, A. J. (2026). Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. Endocrinology, Diabetes & Metabolism, 9(5). https://doi.org/10.1002/edm2.70298
Vancouver
Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, et al. Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. Endocrinology, Diabetes & Metabolism. 2026;9(5). doi:10.1002/edm2.70298
BibTeX
@article{Mohamed2026,
author = {Mohamed, Zakariye Isak and Shidane, Abdinasir Adam and Abdiasis, Abdullahi Mohamud and Hussein, Mohamed Hassan and Ibrahim, Ayaanle Osman and Abdi, Anas Ali and Hashi, Kowthar Ismail and Mohamud, Mohamed Abdullahi and Mohamed, Ali Jimale},
title = {Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {5},
doi = {10.1002/edm2.70298}
}
EUVIMED